- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: C banding.
Displaying page 1 of 1.
EudraCT Number: 2013-003791-12 | Sponsor Protocol Number: 12345 | Start Date*: 2013-10-30 |
Sponsor Name:Helsinki University | ||
Full Title: SIGNAL TRANSDUCTION IN NAFLD | ||
Medical condition: No significant disease other than obesity/type 2 diabetes/hypertension/NAFLD | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005402-11 | Sponsor Protocol Number: GLIDE | Start Date*: 2016-07-08 | |||||||||||
Sponsor Name:Guys and St Thomas NHS Foundation Trust | |||||||||||||
Full Title: The Impact of the Combination of the GLP-1 Analogue Liraglutide (Victoza®) and Laparoscopic Adjustable Gastric Banding (LAGB) on Diabetes Control | |||||||||||||
Medical condition: Type 2 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001318-92 | Sponsor Protocol Number: AP24534-15-303 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib | |||||||||||||
Medical condition: Chronic Phase Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) DK (Prematurely Ended) CZ (Completed) PT (Completed) FR (Completed) AT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006393-14 | Sponsor Protocol Number: UDT-1/PHT | Start Date*: 2007-10-23 | ||||||||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | ||||||||||||||||||
Full Title: Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypert... | ||||||||||||||||||
Medical condition: Portal hypertension, liver cirrhosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) LT (Completed) CZ (Completed) AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003208-30 | Sponsor Protocol Number: RAAINBOW | Start Date*: 2017-11-14 |
Sponsor Name:Legacy Healthcare (France) SAS | ||
Full Title: Double-blind, vehicle-controlled, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp alopecia ar... | ||
Medical condition: Alopecia Areata | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) BG (Completed) FR (Completed) RO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011513-24 | Sponsor Protocol Number: CC-5013-MDS-005 | Start Date*: 2009-12-14 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS PLACEBO IN SUBJECTS WITH TRANSFUSION... | |||||||||||||
Medical condition: TRANSFUSION-DEPENDENT ANEMIA DUE TO IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITHOUT DELETION 5Q [31] AND UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) CZ (Completed) AT (Completed) IT (Completed) PT (Completed) GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002916-34 | Sponsor Protocol Number: ITCC-054/AAML1921 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921 | |||||||||||||
Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001617-12 | Sponsor Protocol Number: AP24534-14-203 | Start Date*: 2017-10-09 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses | |||||||||||||
Medical condition: Chronic Phase Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) DE (Completed) FI (Prematurely Ended) ES (Completed) DK (Completed) NO (Completed) BE (Completed) FR (Trial now transitioned) NL (Completed) PT (Completed) PL (Trial now transitioned) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020414-28 | Sponsor Protocol Number: AP24534-10-201 | Start Date*: 2011-02-21 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia | |||||||||||||
Medical condition: Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) FR (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000227-71 | Sponsor Protocol Number: ITCC-059 | Start Date*: 2016-09-02 | |||||||||||
Sponsor Name:Erasmus Medical Center | |||||||||||||
Full Title: A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia | |||||||||||||
Medical condition: pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) IT (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) PT (Prematurely Ended) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003250-25 | Sponsor Protocol Number: B1871039 | Start Date*: 2014-06-24 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors | |||||||||||||
Medical condition: Philadelphia Chromosome Positive Chronic Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Prematurely Ended) IT (Completed) BE (Completed) NL (Completed) ES (Completed) AT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001355-38 | Sponsor Protocol Number: AP24534-12-301 | Start Date*: 2012-10-04 |
Sponsor Name:ARIAD Pharmaceuticals, Inc | ||
Full Title: A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | ||
Medical condition: Chronic Myeloid Leukemia in Chronic Phase | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Completed) SE (Prematurely Ended) BE (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
